Home / Knowledge Centre /
Case study

How to Add a New Randomized Part to an Ongoing Study in Three Weeks

One of the world’s leading biotechnology companies was focusing on area of highly unmet medical need and developing a pipeline of medicines with breakaway potential to treat some of the toughest cancers.

The Sponsor had a longstanding relationship with Almac Clinical Technologies spanning more than two decades and when they learned from a regulatory agency that they would need to add a new part to the trial, they reached out for Almac’s support on how best to proceed.

This posed a question, when reconfiguring the existing IRT could delay the study for many weeks, could building a new IRT actually be quicker?

In this case study, read about Almac’s approach to rapidly accommodating protocol design configurations and data integration.

View Resource
Almac Logo

Almac Clinical Technologies

Almac Clinical Technologies is here to help the biopharmaceutical industry bring new therapies to those in need by empowering clinical trial sponsors to proactively manage sites, patients, and clinical trial supplies through our industry-leading Interactive Response Technology (IRT) and expert consultancy.

Almac Clinical Technologies is uniquely positioned to unlock new efficiencies in the clinical supply chain and to help achieve greater predictability in your projects and programs.

Our professionals are dedicated to delivering high-quality Interactive Response Technology (IRT) solutions, dependable professional services, and reliable customer service. Our expertise, energy, and commitment have earned us a reputation as a trusted ally in the drug development process.

Learn More

Download here instantly

This website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies